Inside Stayble: February 2021
In the February 2021 edition, CEO Andreas Gerward, discusses the oversubscribed rights issue, next steps and partnering activities.
Inside Stayble is a communication channel aiming to provide shareholders with monthly updates about Stayble Therapeutics and its clinical development program for STA363 in chronic low back pain.
Stayble Therapeutics is listed on Nasdaq First North in Sweden (STABL).
Read more at staybletherapeutics.com